WEC
XENE icon

Winslow Evans & Crocker’s Xenon Pharmaceuticals XENE Stock Holding History

Winslow Evans & Crocker’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,086
Closed -$18.3K – 1345
2015
Q1 		$18.3K Buy
+1,086
New +$20.1K 0.01% 748

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Winslow Evans & Crocker's XENE Position: Q2 2015 in Review

Winslow Evans & Crocker sold out of Xenon Pharmaceuticals (XENE) in Q2 2015, closing a stake of 1,086 shares — an estimated $18.3K sold.

Winslow Evans & Crocker first reported a position in XENE in Q1 2015 and held it in 1 quarter. The position peaked at $18.3K in Q1 2015. 26 funds tracked by Wall St. Rank hold XENE as of Q2 2015.

  • Winslow Evans & Crocker reported no remaining Xenon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Winslow Evans & Crocker sold 1,086 Xenon Pharmaceuticals shares in Q2 2015, an estimated $18.3K.
  • Winslow Evans & Crocker first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Winslow Evans & Crocker's Xenon Pharmaceuticals position peaked at $18.3K in Q1 2015.
  • 26 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2015.

Based on Winslow Evans & Crocker's 13F filing for Q2 2015, filed 23 Jul 2015.